$BSX

BOSTON SCIENTIFIC CORP

CIK:0000885725|SEC Filings

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Net sales	$ 5,442,000,000	$ 5,061,000,000	$ 10,646,000,000	$ 9,724,000,000
Cost of products sold (excluding amortization expense)	1,594,000,000	1,637,000,000	3,184,000,000	3,090,000,000
Gross profit	3,848,000,000	3,424,000,000	7,462,000,000	6,633,000,000
Operating expenses:
Selling, general and administrative expenses	1,803,000,000	1,716,000,000	3,583,000,000	3,312,000,000
Research and development expenses	554,000,000	526,000,000	1,069,000,000	969,000,000
Royalty expense	12,000,000	14,000,000	24,000,000	28,000,000
Amortization expense	233,000,000	225,000,000	466,000,000	444,000,000
Intangible asset impairment charges	0	46,000,000	0	46,000,000
Contingent consideration net expense (benefit)	(16,000,000)	(5,000,000)	(46,000,000)	0
Restructuring net charges (credits)	8,000,000	83,000,000	11,000,000	93,000,000
Litigation-related net charges (credits)	76,000,000	0	76,000,000	0
Operating expenses	2,670,000,000	2,605,000,000	5,183,000,000	4,894,000,000
Operating income (loss)	1,178,000,000	819,000,000	2,279,000,000	1,740,000,000
Other income (expense):
Interest expense	(96,000,000)	(90,000,000)	(186,000,000)	(172,000,000)
Other, net	(23,000,000)	213,000,000	129,000,000	179,000,000
Income (loss) before income taxes	1,060,000,000	941,000,000	2,222,000,000	1,746,000,000
Income tax expense (benefit)	155,000,000	146,000,000	(21,000,000)	279,000,000
Net income (loss)	905,000,000	795,000,000	2,243,000,000	1,467,000,000
Net income (loss) attributable to noncontrolling interests	(2,000,000)	(2,000,000)	(4,000,000)	(4,000,000)
Net income (loss) attributable to Boston Scientific common stockholders	$ 907,000,000	$ 797,000,000	$ 2,247,000,000	$ 1,471,000,000
Net income (loss) per common share — basic	$ 0.62	$ 0.54	$ 1.52	$ 0.99
Net income (loss) per common share — diluted	$ 0.61	$ 0.53	$ 1.51	$ 0.98
Weighted-average shares outstanding
Basic	1,470.2	1,479.9	1,477.6	1,478.5
Diluted	1,474.8	1,493.5	1,484.9	1,493.3

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash provided by (used for) operating activities
Net income (loss)	$ 2,243	$ 1,467
Depreciation and amortization	706	661
Deferred and prepaid income taxes	(334)	(49)
Stock-based compensation expense	170	149
Goodwill and other intangible asset impairment charges	0	46
Net loss (gain) on investments and notes receivable	(146)	(191)
Contingent consideration net expense (benefit)	(46)	0
Inventory step-up amortization	6	118
Other, net	63	72
Trade accounts receivable	(163)	(139)
Inventories	(310)	(44)
Other assets	(90)	(108)
Accounts payable, accrued expenses and other liabilities	(278)	(154)
Cash provided by (used for) operating activities	1,822	1,827
Investing activities:
Purchases of property, plant and equipment and internal use software	(372)	(344)
Payments for acquisitions of businesses, net of cash acquired	(718)	(1,248)
Proceeds from sale of investments and dispositions of certain technologies	229	55
Payments for investments and acquisitions of certain technologies	(1,730)	(165)
Other, net	43	76
Cash provided by (used for) investing activities	(2,547)	(1,626)
Financing activities:
Payment of contingent consideration previously established in purchase accounting	(78)	(62)
Payments for finance leases	0	(42)
Payments on short-term borrowings	(272)	(1,583)
Net increase (decrease) in commercial paper	1,675	1
Proceeds from long-term borrowings, net of debt issuance costs	0	1,558
Cash used to net share settle employee equity awards	(88)	(123)
Payments for Repurchase of Common Stock	(2,000)	0
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans	86	147
Other, net	8	(3)
Cash provided by (used for) financing activities	(670)	(107)
Effect of foreign exchange rates on cash	1	41
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	(1,394)	135
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	2,147	606
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	753	741
Cash and cash equivalents	539	534
Restricted cash and restricted cash equivalents included in Other current assets	81	109
Restricted cash equivalents included in Other long-term assets	133	98
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$ 753	$ 741

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 539	$ 1,965
Trade accounts receivable, net	3,049	2,926
Inventories	3,235	2,943
Prepaid income taxes	390	299
Other current assets	760	660
Total current assets	7,972	8,794
Other investments	2,245	681
Property, plant and equipment, net	4,126	4,036
Goodwill	18,640	18,282
Other intangible assets, net	6,918	7,019
Deferred tax assets	3,909	3,675
Other long-term assets	1,405	1,185
TOTAL ASSETS	45,216	43,673
Current liabilities:
Current debt obligations	1,709	299
Accounts payable	1,231	1,144
Accrued expenses	2,756	3,201
Other current liabilities	732	795
Total current liabilities	6,428	5,439
Long-term debt	10,915	11,137
Deferred tax liabilities	221	220
Other long-term liabilities	2,480	2,405
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2026 and December 31, 2025	0	0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - 1,749,917,975 shares issued as of June 30, 2026 and 1,746,290,165 shares issued as of December 31, 2025	17	17
Treasury stock, at cost - 303,212,284 shares as of June 30, 2026 and 263,289,848 shares as of December 31, 2025	(4,318)	(2,251)
Additional paid-in capital	21,717	21,505
Retained earnings	7,818	5,571
Accumulated other comprehensive income (loss), net of tax	(304)	(610)
Total stockholders’ equity	24,930	24,233
Noncontrolling interests	242	239
Total equity	25,172	24,472
TOTAL LIABILITIES AND EQUITY	$ 45,216	$ 43,673